Brief Use of CGM May Enhance Lifestyle Awareness in T2D
Short-term use of continuous glucose monitoring (CGM) provided valuable insights into lifestyle factors affecting blood glucose levels in people with type 2 diabetes (T2D) who were not on insulin therapy, particularly in those with a diabetes duration of less than 5 years.
METHODOLOGY:
CGM is an effective strategy for managing blood glucose levels in people with non-insulin-treated T2D; this study focused on the insights gained regarding lifestyle factors affecting blood glucose levels over a 2-week period of usage.
Participants with non-insulin-treated T2D across 20 cities in Denmark received a single CGM device during a walk-in setup, with minimal guidance provided during device installation.
They used the CGM device for a maximum of 14 days.
Baseline questionnaires were completed onsite, with follow-up surveys sent via email after 2 weeks and after 3 months.
TAKEAWAY:
A total of 724 participants completed the second questionnaire sent after 2 weeks.
Of these, 80% found CGM highly useful and informative for managing T2D.
Participants with a diabetes duration of less than 5 years engaged in more daily scans (80% vs 71%) and reported greater insights into the effects of lifestyle on glucose levels — including food (88% vs 78%), portion sizes (80% vs 60%), and physical activity (65% vs 55%) — than those with a diabetes duration of more than 5 years.
Education level did not significantly affect the knowledge gained from CGM usage.
At the 3-month follow-up, 50% of participants reported maintaining behavioral changes based on their CGM experience.
IN PRACTICE:
"These insights may encourage long-term behavioral changes, potentially leading to improved glycemic control," the authors wrote.
SOURCE:
The study was led by Emma Munch Nielsen, Glostrup, Denmark. It was presented by Tanja Thybo, Glostrup, Denmark, on June 20, 2025, at the 85th Scientific Sessions - American Diabetes Association, held at the McCormick Place Convention Center, Chicago.
LIMITATIONS:
No limitations were discussed in the abstract.
DISCLOSURES:
No funding details were disclosed. Three authors disclosed relationships with Abbott.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Former Chief Software Architect and Technology Advisor of Ontario Ministry of Health Orchestrates Groundbreaking Transformation in AI-Driven Cancer Diagnostics and National Healthcare Equity
We are not just building smarter systems; we are creating a future where every patient, no matter their background, has access to life-saving care. Artificial Intelligence is transforming cancer diagnostics in Canada, enabling earlier detection, improved accuracy, and equitable access to care. At the forefront of this shift is Hugo Raposo, former Chief Software Architect and Technology Advisor for the Ontario Ministry of Health, whose work integrates machine learning and precision medicine into healthcare systems to bridge gaps for underserved communities. These innovations are setting new standards for ethical and personalized care. Hugo Raposo, one of Canada's foremost technology visionaries and the former Chief Software Architect and Technology Advisor for the Ontario Ministry of Health, is leading a nationwide transformation that is redefining the future of cancer care through Artificial Intelligence (AI). With nearly three decades of distinguished expertise in digital health transformation, enterprise architecture, and AI strategy, Raposo is setting a new benchmark for innovation at the intersection of technology and public health. At a time when cancer rates are projected to increase by over 60% globally in the next two decades, Raposo's initiatives arrive as a beacon of innovation and hope. He has spearheaded the development of intelligent healthcare platforms that integrate advanced machine learning, deep neural networks, and precision medicine into the core of cancer diagnostics. These groundbreaking advancements are not only enabling earlier and more accurate detection of malignancies but are also systematically dismantling the structural inequities that have long limited access to life-saving care for millions of Canadians. Driving the Intelligent Future of Cancer Care Raposo's vision comes to life in advanced AI systems designed to process and interpret vast, intricate medical imaging datasets with remarkable precision—spanning MRIs, CT scans, mammograms, and PET scans—to identify subtle, early indicators of cancer that frequently evade conventional diagnostic workflows. Under his leadership, these AI-powered solutions have achieved diagnostic performance on par with, and often surpassing, the most experienced human radiologists. This paradigm shift is transforming the diagnostic landscape by reducing variability, accelerating time-to-treatment, and delivering equitable outcomes across diverse populations. 'Artificial Intelligence is no longer a theoretical concept; it is a strategic necessity for healthcare systems intent on delivering equitable, high-quality outcomes,' stated Raposo. 'By embedding AI within our national healthcare infrastructure, we are not only bridging geographic and socioeconomic divides but also creating a scalable model for precision cancer care that can transform lives and future-proof our healthcare systems.' A Vision for National Health Equity Under Raposo's direction, AI-enabled portable imaging devices and secure, cloud-connected diagnostic platforms are being deployed in rural and underserved communities. These cutting-edge tools empower general practitioners and community health workers to conduct sophisticated cancer screenings with unprecedented accuracy. This approach has been instrumental in reducing diagnostic delays and ensuring that no Canadian's health outcome is determined by where they live or their socioeconomic status. 'Equity is not a byproduct of innovation; it must be embedded into every layer of our technological and clinical strategy,' Raposo emphasized. 'We are building systems that serve all Canadians equally, ensuring ethical guardrails, inclusivity, and fairness are central to every deployment.' By integrating multidimensional datasets—including genomic profiles, environmental factors, and behavioral patterns—Raposo's initiatives are advancing personalized oncology at scale. Predictive AI models designed under his stewardship enable clinicians to tailor screening protocols and treatment regimens to individual patients, maximizing clinical efficacy while minimizing unnecessary interventions and driving cost-effectiveness across Canada's healthcare system. Global Thought Leadership on Ethical AI Beyond his technical achievements, Raposo has emerged as a global authority on the ethical deployment of AI in healthcare. Recognizing the critical importance of data privacy, algorithmic fairness, and system transparency, he has championed frameworks that ensure AI technologies benefit all populations equitably. His contributions have made him a sought-after advisor to policymakers, health ministers, and international organizations striving to adopt AI responsibly and sustainably. 'Trust is the bedrock of transformative healthcare,' said Raposo. 'Our systems are designed with uncompromising commitments to patient privacy, data security, and algorithmic explainability to maintain public confidence and achieve long-term societal impact.' Expanding AI's Role in Canada's Healthcare Renaissance Raposo's work extends to fostering collaboration between technologists, clinicians, and public health leaders to create AI ecosystems that are robust, transparent, and adaptable. By cultivating partnerships with both public and private stakeholders, he has accelerated the integration of AI-driven tools into primary care and oncology programs nationwide. These initiatives have established Canada as a model for other nations seeking to modernize their healthcare systems while remaining attentive to ethical and equitable implementation. As AI becomes increasingly central to healthcare delivery, Raposo emphasizes the need for continuous innovation and vigilance. He has advocated for the creation of inclusive data repositories to ensure that AI models are trained on diverse and representative datasets. This effort is crucial to preventing algorithmic bias and achieving diagnostic accuracy across all demographic groups. About Hugo Raposo Hugo Raposo is a globally recognized Technology Advisor, Enterprise Architect, and AI Strategist who has dedicated his career to transforming healthcare systems through innovation. As the former Chief Software Architect and Technology Advisor for the Ontario Ministry of Health, he conceptualized and led transformative initiatives that modernized critical public health platforms. Under his leadership, scalable AI-powered diagnostic solutions were developed to improve outcomes for millions of citizens. Today, Raposo continues to shape the future of global healthcare, driving equitable access and ethical AI integration to redefine cancer care for the 21st century. Media Contact Company Name: Knewin Dino Contact Person: Caroline Silva Email: Send Email Country: Brazil Website: Press Release Distributed by To view the original version on ABNewswire visit: Former Chief Software Architect and Technology Advisor of Ontario Ministry of Health Orchestrates Groundbreaking Transformation in AI-Driven Cancer Diagnostics and National Healthcare Equity
Bloomberg
an hour ago
- Bloomberg
KKR Mulls Acquisition of Health-Care Technology Firm GPI
KKR & Co., the buyout firm that's been scouting for takeover targets amid the recent market volatility, is considering a potential acquisition of Italian health-care technology firm GPI SpA, according to people with knowledge of the matter. The US private equity firm has been speaking with advisers in recent weeks as it considers a potential deal to take Trent-based GPI private, the people said, asking not to be identified as the matter is private. Shares of GPI have risen 24% in Milan trading this year, giving the company a market value of about €377 million ($438 million).
Yahoo
2 hours ago
- Yahoo
Virtua Health and ChristianaCare are discussing a new nonprofit venture. What we know.
Virtua Health and ChristianaCare are in talks to co-found a new regional nonprofit health system that would provide care to more than 600 sites in New Jersey, Delaware, Pennsylvania and Maryland. The two health care players, based in Marlton, New Jersey and Wilmington, Delaware, signed a non-binding letter of intent to explore the idea of the co-founded health system, according to a July 16 joint press release. If established, the new health system would not only serve more than 10 contiguous counties throughout the states, but would also support nearly 30,000 employees, plus 500 residents and fellows through academic programs, the press release said. More: What's happening with the Olsen Building, a landmark in Camden's Waterfront South? In addition, the prospective system includes a proposed maternal risk program to support more than 15,000 mothers and babies yearly. Dennis W. Pullin, president and chief executive officer of Virtua Health, called the signing an "exciting first step" in the release. "We see this as a unique opportunity to shape the future of care in this region with innovation and intention," Pullin said. Janice E. Nevin, president and chief executive officer of ChristianaCare shared this same sentiment. "At a time of great uncertainty in health care, ChristianaCare and Virtua Health have the foresight and courage to explore what is possible," Nevin said. The partnership is one that health network executives said has the potential to "multiply excellence" in the sector by making health care easier to navigate, more personalized and convenient, building on the expertise from both Virtua Health and ChristianaCare. The announcement also comes as U.S. President Donal Trump's latest legislation package, dubbed the "Big, Beautiful Bill," threatens health care coverage across the country with cuts to Medicaid and Medicare funding. In the press release, George N. Foutrakis, chair of the ChristianaCare Health System Board, addressed the hardships being faced within the realm of health and patient care. "Our vision for this new health system — when Medicare and Medicaid are facing cuts and many hospitals are struggling to stay open — gives me hope and excitement for our future and for the health of our neighbors," Foutrakis said. Though the co-signed letter of intention is non-binding, representatives of both networks seem hopeful in the potential of this new vision. Moving forward, the release stated, both Virtua Health and ChristianaCare will operate separately and independently while continuing to negotiate, seek regulatory approvals and sign various definitive agreements. Kaitlyn McCormick writes about trending issues and community news across South Jersey for the Courier-Post, The Daily Journal and the Burlington County Times. If you have a story she should tell, email her at kmccormick@ And subscribe to stay up to date on the news you need. This article originally appeared on Cherry Hill Courier-Post: Virtua Health, ChristianaCare in talks for new regional health system Solve the daily Crossword
